Myopia Control for Children in Brooklyn
When a child's distance prescription keeps increasing, parents naturally want to know whether anything can slow the change. Myopia management addresses that question. Its aim is not simply clearer vision today, but a slower rate of progression during the years when the eyes are still growing.
Classic Vision Optical & Optician provides Essilor Stellest lenses in Borough Park, Brooklyn. We help families understand the eyewear choices while the prescribing clinician determines eligibility, treatment, and monitoring. Here is how several evidence-based approaches differ, including the important distinction between FDA-authorized treatment and off-label prescribing.
Why childhood myopia deserves attention
Myopia, or nearsightedness, makes distant objects appear blurred. The FDA reports that its prevalence is rising in the United States and worldwide, including among children and adolescents. Myopia commonly progresses during school age while the eyes are growing and may level off in early adulthood.
The concern is not only a thicker prescription. Higher myopia is associated with greater risk of retinal detachment, myopic maculopathy, glaucoma, and cataracts later in life. Treatment discussions therefore consider both the child's current visual needs and the longer-term implications of progression.
No option guarantees that a child's prescription will stop changing. Ask the clinician how progression will be assessed, what outcome would count as a useful response, and what might lead to changing the plan. Studies of different treatments cannot be ranked casually when their participants, methods, and comparison groups differ.
Essilor Stellest: FDA-authorized spectacle lenses
On September 25, 2025, the FDA granted Essilor Stellest De Novo marketing authorization for correcting myopia, with or without astigmatism, and slowing progression in children ages 6–12 at initiation. The labeled indication specifies non-diseased eyes, spherical equivalent refraction from -0.75 D to -4.50 D, and astigmatism up to 1.50 D.
Stellest combines a central clear area with surrounding peripheral lenslets. The FDA describes these lenslets as providing peripheral light defocus that may help slow progression. This is a specialized treatment design, not simply a standard prescription lens with an added surface coating.
In the two-year study evaluated by the FDA, Stellest reduced prescription progression by 71% and axial elongation by 53% compared with single-vision control lenses. Those are group comparisons over a defined study period, not guaranteed outcomes for an individual child. Some participants reported blur or halos. Classic Vision provides Stellest and can discuss the eyewear requirements after clinical suitability is established.
MiSight: FDA-approved daily disposable contact lenses
MiSight 1 day contact lenses have FDA approval for correcting myopia and slowing progression in children who begin treatment at ages 8–12. The original FDA labeling specifies non-diseased eyes, spherical equivalent refraction from -0.75 D to -4.00 D, and astigmatism of 0.75 D or less.
These are soft, single-use contact lenses worn during the day and discarded after removal. They are not approved for overnight wear. Contact lens suitability involves more than age: the prescribing professional must consider the child's ability to follow wear, hygiene, and replacement instructions.
Contact lenses can carry risks, including infection. Discuss benefits, responsibilities, and follow-up with a qualified contact lens practitioner. This comparison is educational; Classic Vision's myopia-management offering described here is Stellest, not a claim that MiSight fitting or every treatment listed is available at the shop.
Low-dose atropine: an off-label medical option
Low-dose atropine eye drops are used by clinicians to try to slow childhood myopia. Their use for myopia is off-label in the United States, rather than an FDA-approved myopia indication. AAO guidance explains that atropine has an FDA-approved use for amblyopia, but that does not make every concentration or myopia treatment regimen FDA-approved.
The evidence is not identical across concentrations and populations. The AAO describes mixed trial findings, including differing results with very low concentrations. A clinician should explain why a particular preparation is being considered, what side effects to watch for, and how response will be monitored.
Atropine does not replace the optical correction needed for clear distance vision. Do not start, change, combine, or stop medication based on an eyewear comparison page. Medical prescribing and treatment adjustments belong with the child's treating clinician, who can assess the whole clinical picture.
Outdoor time and a coordinated follow-up plan
The AAO encourages children to spend more time outdoors and balance near-focused activities with outdoor activity. Evidence supporting outdoor time is particularly relevant to reducing the likelihood of myopia developing. It should not be presented as equivalent to an authorized treatment for a child whose myopia is already progressing.
Outdoor activity is a behavioral recommendation, not an FDA-approved drug or device. It can be part of a broader plan without replacing prescribed glasses, medication, or scheduled reviews. Avoid framing the problem as a parent's fault or claiming that screens alone explain every child's myopia.
Bring previous prescriptions and the current glasses when discussing options. Ask about eligibility, daily treatment responsibilities, examination intervals, and whether eye-length measurement is appropriate and available through the treating practice. For Stellest inquiries, call, text, or WhatsApp Classic Vision at (718) 621-5717. Sunday-morning consultations with Yossi and Shaul can be requested through the booking page on this site.
Frequently asked
- Can glasses slow my child's myopia?
- Some specialized lenses can. Essilor Stellest received FDA De Novo marketing authorization on September 25, 2025, for eligible children ages 6–12 at initiation. Ordinary single-vision correction should not be assumed to provide the same treatment effect.
- Is Stellest available at Classic Vision in Brooklyn?
- Yes. Classic Vision provides Stellest at 5314 18th Ave in Borough Park. A prescribing clinician must establish suitability, including the labeled age and prescription requirements, and arrange appropriate monitoring.
- Are low-dose atropine drops FDA-approved for myopia?
- No. Their use for myopia is off-label in the United States. Evidence varies by concentration and study population, so treatment decisions and monitoring should be discussed with the child's clinician.
- What ages are covered by MiSight's FDA approval?
- The FDA-approved indication covers children beginning treatment at ages 8–12, within specified prescription limits. Suitability also requires a contact lens assessment and the ability to follow wear and hygiene instructions.
- Can outdoor time replace myopia treatment?
- No. Outdoor time is a helpful behavioral recommendation, especially for reducing myopia onset risk, but it should not replace prescribed treatment or follow-up for a child with progressing myopia.
Any lens, from every major maker — measured, fitted and adjusted by hand at 5314 18th Ave.